Jean M Silva

US Patent:

20060194740, Aug 31, 2006

Filed:

Feb 23, 2006

Appl. No.:

11/361015

Inventors:

Richard Ulevitch - Del Mar CA, US
Jean Silva - San Diego CA, US
Jiahuai Han - San Diego CA, US

International Classification:

A61K 48/00
A61K 38/04

US Classification:

514019000, 514044000

Abstract:

The invention provides compositions and methods for treating tumors that involve increasing the expression of Nod1 and/or the activity of NOD1.

US Patent:

20090028795, Jan 29, 2009

Filed:

Feb 27, 2006

Appl. No.:

11/884898

Inventors:

Richard J. Ulevitch - La Jolla CA, US
Jean da Silva - San Diego CA, US
Jiahuai Han - San Diego CA, US

International Classification:

A61K 49/00
A61K 38/07
A61K 31/195
A61K 38/05
A61K 38/19
A61K 31/7088
A61P 35/00
A61K 31/56
C12N 5/08
G01N 33/53

US Classification:

424 92, 514 18, 514563, 514 19, 424 851, 514182, 435371, 435 71, 514 44

Abstract:

The invention provides compositions and methods for treating tumors that involve increasing the expression of Nod1 and/or the activity of NOD1.

US Patent:

20120021995, Jan 26, 2012

Filed:

Jul 26, 2011

Appl. No.:

13/190914

Inventors:

Katherine Bowdish - Del Mar CA, US
Mark Renshaw - San Diego CA, US
Bing Lin - San Diego CA, US
Jean de Silva Correia - San Diego CA, US
Roger Ferrini - San Diego CA, US
Elise Chen - Del Mar CA, US

Assignee:

ANAPHORE, INC. - La Jolla CA

International Classification:

A61K 38/16
A61P 35/00
A61K 38/10
C07K 7/04
C07K 14/00

US Classification:

514 193, 530326, 530324

Abstract:

Agonists for TRAIL death receptors including polypeptides that bind to TRAIL death receptor TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5) and optionally having a multimerizing, e.g. trimerizing domain. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.

US Patent:

20220363759, Nov 17, 2022

Filed:

May 3, 2022

Appl. No.:

17/661841

Inventors:

- San Diego CA, US
David J. KING - Encinitas CA, US
Jean DA SILVA CORREIA - San Diego CA, US

International Classification:

C07K 16/28
A61P 37/00
A61P 35/00

Abstract:

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.

US Patent:

20180127500, May 10, 2018

Filed:

Apr 1, 2016

Appl. No.:

15/563924

Inventors:

- San Diego CA, US
David J. KING - Encinitas CA, US
Jean DA SILVA CORREIA - San Diego CA, US

International Classification:

C07K 16/28
A61P 35/00
A61P 37/00

Abstract:

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (HM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.